← Leaderboards
Ji Qiu
Arizona State University-Tempe Campus
$3,239,424
Attributed
$5,926,494
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,926,494 · 5
By mechanism
R01$5,374,141 · 3
R21$552,353 · 2
Top collaborators
- Joshua Labaer8 shared
- Lajos Pusztai2 shared
Most similar at Arizona State University-Tempe Campus
Same institution · by research overlap
- Lajos Pusztai$3,364,076
- Joshua Labaer$45,532,384
- Jessica Diane Weaver$3,635,724
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsProtein ArrayImmune ResponsePerformanceAntibodiesAntigensSamplingSerumProteomeMalignant NeoplasmsDiagnosisDetectionTechnologyBlindedInnovationBaseResponseEnzyme-Linked Immunosorbent AssayEnsureHigh RiskAutoantibodiesProteomicsPathogenesisValidation
Grant awards (13)
Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer$643,798
R01 · FY2025 · CA · contact PI
Glyco-MAP: a high-throughput multiplexed platform for Glycosylated Mucin Antibody Profiling with glycoengineered cell lines expressing well-defined homogeneous glycostructures$183,494
R21 · FY2025 · CA · contact PI
Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer$671,146
R01 · FY2024 · CA · contact PI
Identification of Anti-Neo-Antigen AutoAntibodies in Type 1 Diabetes$544,476
R01 · FY2020 · DK
Identification of Anti-Neo-Antigen AutoAntibodies in Type 1 Diabetes$544,476
R01 · FY2019 · DK
Exploiting the immune response to detect pathogen-induced cancers$469,506
R01 · FY2019 · CA
Identification of Anti-Neo-Antigen AutoAntibodies in Type 1 Diabetes$557,343
R01 · FY2018 · DK
Exploiting the immune response to detect pathogen-induced cancers$492,377
R01 · FY2018 · CA
Exploiting the immune response to detect pathogen-induced cancers$436,974
R01 · FY2017 · CA
Exploiting the immune response to detect pathogen-induced cancers$496,815
R01 · FY2016 · CA
Exploiting the immune response to detect pathogen-induced cancers$517,230
R01 · FY2015 · CA
A protein array platform for anti-citrulline antibodies in Rheumatoid Arthritis$162,984
R21 · FY2013 · AR · contact PI
A protein array platform for anti-citrulline antibodies in Rheumatoid Arthritis$205,875
R21 · FY2012 · AR · contact PI